DNA METHYLATION IN BLOOD LYMPHOCYTES AND RISK OF LUNG CANCER

Sofia Pavanello, Occupational Health Section, Department of Environmental Medicine and Public Health, Università di Padova, Padova, Italy
Andrea Baccarelli, Environmental Health Department, Harvard School of Public Health, Boston, Massachusetts, United States of America
Michele Carugno, Department of Occupational and Environmental Health, Università degli Studi di Milano, Milan, Italy
Letizia Tarantini, Department of Occupational and Environmental Health, Università degli Studi di Milano, Milan, Italy
Laura Cantone, Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy
Valentina Bollati, Department of Occupational and Environmental Health, Università degli Studi di Milano, Milan, Italy
Kim Overvad, Department of Epidemiology, School of Public Health, Aarhus University, Aarhus, Denmark
Anne Tjønneland, Department of Epidemiology, School of Public Health, Aarhus University, Aarhus, Denmark
Ulla Vogel, Institute for Science, Systems and Models, Roskilde University, Roskilde, Denmark
Angela Cecilia Pesatori, Department of Occupational and Environmental Health, Università degli Studi di Milano, and Fondazione IRCCS Ca’ Granda - Ospedale Maggiore Policlinico, Milan, Italy

Background and Aims: Aberrant DNA methylation is a common event in cancer development, lung cancer included. Aim of our study is to determine whether alterations in global and gene-specific DNA methylation in peripheral blood lymphocytes (PBLs) can precede and thus predict lung cancer development.

Methods: The study subjects were selected from a Danish prospective study and were free-of-cancer at the enrollment (1993-1997). Blood samples and information on life-style (smoking habits, diet) were collected. 276 lung cancer cases were diagnosed (1994-2003) and a sub-cohort of 303 controls was selected and frequency matched on sex and age according to the case-cohort design. Methylation state of LINE-1 repetitive elements (global methylation) and of gene-specific promoters of microRNA124a, tumor suppressor (p16, RASSF1A, DAPK), DNA-repair (MSH2, MGMT, hMLH1) and cell-proliferation genes (CDH1, CDH13, RARβ) was measured in PBLs by PCR-Pyrosequencing. Hazard Ratios (HR) for lung cancer were estimated with Cox models, adjusted for age, sex, and smoking status. We created gene-specific dichotomous variables (equal to 0 or 1 if methylation lays below or above the 75th percentile of each gene-specific distribution, respectively) and summed them (excluding LINE-1) to calculate methylation indexes for overall methylation (MI), tumor suppressor genes (TSGI), DNA-repair genes (DRGI), and cell-proliferation genes (CPGI).

Results: Gene-specific methylation indexes were significantly positively associated with lung cancer risk for MI, TSGI and DRGI [HR=1.25 (95%CI 1.14-1.36; p<0.001), HR=1.19 (95%CI 1.02-1.38; p=0.030) and HR =1.59 (95%CI 1.35-1.87; p<0.001)] but not for CPGI and microRNA124a [HR=1.09 (95%CI 0.92-1.29; p=0.301) and HR=1.10 (95%CI 0.84-1.44; p=0.502)]. LINE-1 index was inversely correlated with lung cancer risk [HR=0.13 (95%CI 0.07-0.22; p<0.001)].

Conclusions: Specific methylation tumorigenic patterns are found in PBLs (in particular DNA-repair and tumor suppressor gene hypermethylation together with LINE-1 hypomethylation) and precede lung cancer development. Such results suggest how DNA methylation changes could be predictive of lung cancer risk.